Alto Neuroscience (NYSE:ANRO) shares nosedived 66% Wednesday morning, the first trading session, after the company announced its psychiatric drug ALTO-100 had failed a key clinical study. After ...

Alto Neuroscience hit a bum note in an early test of its precision neuropsychiatry model. A phase 2b trial of Alto’s lead drug candidate in depression missed its primary and key secondary ...

Strong cash position expected to fund Alto’s planned operations through multiple near-term milestones across pipeline of independent programs – MOUNTAIN VIEW, Calif., October 22, 2024 ...

California Gov. Gavin Newsom and Elon Musk at Tesla’s new global engineering and AI headquarters in Palo Alto on Feb. 22, 2023. Courtesy Office of Gov. Gavin Newsom. As the city weighs the ...